ERBB2 and breast cancer: While only 10% of all types of breast cancer in the dataset were identified as HER2+, the HER2+ subtype existed in 30% (3-fold more, p = 3.6e−13) of the WIP1-amplified breast cancers, compared to 7% of breast cancers without WIP1 amplification (Fig. 1c).